Lin Health is a technology company.
Lin Health has raised $5.0M across 1 funding round.
Lin Health has raised $5.0M in total across 1 funding round.
Lin Health has raised $5.0M in total across 1 funding round.
Lin Health's investors include Altair Capital Management, Btomorrow Ventures, Fuel Ventures, Viola Ventures, Richard Longhurst.
Lin Health is a digital health technology company that provides evidence-based chronic pain treatment through a collaborative care model powered by proprietary technology. It partners with providers and payers to deliver personalized, low-risk care alternatives to opioids, targeting the nervous system with multidisciplinary coaching, digital resources, and clinical guidance to achieve lasting pain relief.[1][2] Serving patients suffering from chronic primary pain—affecting one in five Americans—the platform solves the problem of persistent pain by addressing bio-psycho-social factors rather than tissue damage, using techniques validated under the ICD-11 framework; it offers quick access (within days), insurance coverage (including Medicare and most major plans), and high outcomes like 98% improvement and 75% achieving pain-free or nearly pain-free status.[1][2] Growth momentum includes an $11M funding raise to scale its digital platform, which pairs patients with recovery coaches for tailored plans.[3]
Lin Health emerged to address the chronic pain crisis, with a mission to reclaim lives using the latest pain neuroscience and behavioral health advancements via the Collaborative Care model.[1] While specific founders are not detailed in available sources, the company is guided by a leadership team and a Clinical Advisory Panel, including experts like Dr. Shaheen Lakhan, MD, who contributed to the ICD-11 chronic primary pain code that underpins their approach.[1][2] Early traction stems from patient testimonials of years-long relief after failed traditional treatments, positioning Lin as a pioneer in nervous system signaling techniques for the 80% of persistent pain cases now classified under ICD-11.[2] Pivotal moments include clinical validation of their interventions and partnerships with health plans, enabling rapid scaling.[1][2][3]
Lin Health rides the wave of digital health innovations in pain management, shifting from opioid reliance to non-pharmacological, neuroscience-backed interventions amid the U.S. chronic pain epidemic affecting 20% of adults.[1][2] Timing aligns with ICD-11's reclassification of primary chronic pain, enabling validated, scalable digital solutions over outdated tissue-damage models.[2] Market forces like payer demands for cost-effective, covered care, provider burnout, and post-opioid crisis reforms favor Lin's model, which integrates with existing systems to expand access without silos.[1][2] It influences the ecosystem by pioneering collaborative digital platforms, improving outcomes, satisfaction, and clinic efficiency while setting a standard for bio-psycho-social pain tech.[2][3]
Lin Health is poised to expand its $11M-funded platform, deepening integrations with payers and providers to capture more of the massive chronic pain market.[3] Trends like AI-enhanced coaching, broader ICD-11 adoption, and value-based care will accelerate growth, potentially positioning it as a leader in preventive behavioral health tech. Its influence may evolve by standardizing nervous system-focused pain recovery, reducing societal opioid burdens and inspiring similar models in mental health—reclaiming lives at scale, as its mission promises.[1][2][3]
Lin Health has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Series A in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $5.0M Series A | Altair Capital Management, Btomorrow Ventures, Fuel Ventures, Viola Ventures, Richard Longhurst |